Targeted treatments in colorectal cancer: state of the art and future perspectives.
Standard
Targeted treatments in colorectal cancer: state of the art and future perspectives. / Arnold, Dirk; Seufferlein, Thomas.
in: GUT, Jahrgang 59, Nr. 6, 6, 2010, S. 838-858.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Targeted treatments in colorectal cancer: state of the art and future perspectives.
AU - Arnold, Dirk
AU - Seufferlein, Thomas
PY - 2010
Y1 - 2010
N2 - Targeted treatments have generated a lot of hope and hype in the treatment of gastrointestinal tumours. Indeed, the introduction of targeted treatments particularly for colorectal cancer has resulted in substantial improvements in tumour response and progression-free survival of patients. However, it is not fully understood how these agents act in patients, and the preclinical models are not appropriate to predict clinical efficacy. Here the current state of targeted treatments in colorectal cancer is reviewed, focusing on antiepidermal growth factor receptor (EGFR) and antiangiogenic strategies, describing how these agents fit into the therapeutic algorithm of this disease and discussing current understanding of the mechanism of action, biomarkers as well as future therapeutic strategies targeting multiple signalling pathways in colorectal cancer.
AB - Targeted treatments have generated a lot of hope and hype in the treatment of gastrointestinal tumours. Indeed, the introduction of targeted treatments particularly for colorectal cancer has resulted in substantial improvements in tumour response and progression-free survival of patients. However, it is not fully understood how these agents act in patients, and the preclinical models are not appropriate to predict clinical efficacy. Here the current state of targeted treatments in colorectal cancer is reviewed, focusing on antiepidermal growth factor receptor (EGFR) and antiangiogenic strategies, describing how these agents fit into the therapeutic algorithm of this disease and discussing current understanding of the mechanism of action, biomarkers as well as future therapeutic strategies targeting multiple signalling pathways in colorectal cancer.
KW - Humans
KW - inhibitors
KW - Protein Kinase Inhibitors pharmacology
KW - Antibodies, Monoclonal therapeutic use
KW - Mutation
KW - Genetic Markers
KW - Signal Transduction drug effects
KW - Colorectal Neoplasms drug therapy
KW - Angiogenesis Inhibitors therapeutic use
KW - Antineoplastic Agents pharmacology
KW - Genes, ras genetics
KW - Receptor, Epidermal Growth Factor antagonists
KW - Humans
KW - inhibitors
KW - Protein Kinase Inhibitors pharmacology
KW - Antibodies, Monoclonal therapeutic use
KW - Mutation
KW - Genetic Markers
KW - Signal Transduction drug effects
KW - Colorectal Neoplasms drug therapy
KW - Angiogenesis Inhibitors therapeutic use
KW - Antineoplastic Agents pharmacology
KW - Genes, ras genetics
KW - Receptor, Epidermal Growth Factor antagonists
M3 - SCORING: Zeitschriftenaufsatz
VL - 59
SP - 838
EP - 858
JO - GUT
JF - GUT
SN - 0017-5749
IS - 6
M1 - 6
ER -
